Literature DB >> 18568145

Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum.

Camelia Ionescu1, Laurenţiu Micu, Ileana Constantinescu, Monica Hortopan, Cornel Ursaciuc, Mihai Voiculescu.   

Abstract

The antiviral treatment of chronic C hepatitis has improved significantly over the past decade with the introduction of interferons (IFNs), and more recently, pegylated IFNs. Up to two-thirds of all patients treated with pegylated IFN combined with ribavirin can now achieve viral eradication if treated according to current guidelines. Despite this success rate, hematological, immunological, rheumatological and dermatological side effects have been reported in chronic hepatitis C patients treated with IFN-alpha. The subjects of this report are two young females with chronic hepatitis C, who developed rheumatoid syndrome and/or erythema nodosum during antiviral treatment with IFN-alpha or pegylated IFN combined with ribavirin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568145     DOI: 10.1007/s11749-008-0114-x

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  6 in total

Review 1.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

Review 2.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

Review 3.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

4.  Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.

Authors:  Bruno Cacopardo; Francesco Benanti; Marilia Rita Pinzone; Giuseppe Nunnari
Journal:  BMC Res Notes       Date:  2013-10-30

5.  Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis.

Authors:  Waka Yokoyama-Kokuryo; Hayato Yamazaki; Tsutomu Takeuchi; Koichi Amano; Jun Kikuchi; Tsuneo Kondo; Seiji Nakamura; Ryoko Sakai; Fumio Hirano; Toshihiro Nanki; Ryuji Koike; Masayoshi Harigai
Journal:  Arthritis Res Ther       Date:  2020-03-12       Impact factor: 5.156

6.  IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA.

Authors:  Qingcong Zheng; Du Wang; Rongjie Lin; Qi Lv; Wanming Wang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.